Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma.

Trial Profile

Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2017

At a glance

  • Drugs Monoclonal antibody 3F8 (Primary) ; Cyclophosphamide; Leukocyte cell therapy; Topotecan; Vincristine
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
    • 01 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 01 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top